These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36639036)
1. Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment. Zhang R; Luo Y; Du C; Wu L; Wang Y; Chen Y; Li S; Jiang X; Xie Y Bioorg Med Chem Lett; 2023 Feb; 81():129128. PubMed ID: 36639036 [TBL] [Abstract][Full Text] [Related]
2. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer. Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178 [TBL] [Abstract][Full Text] [Related]
3. Single protein encapsulated SN38 for tumor-targeting treatment. Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965 [TBL] [Abstract][Full Text] [Related]
4. A novel irinotecan derivative ZBH-1207 with different anti-tumor mechanism from CPT-11 against colon cancer cells. Zhao D; Wu D; Zhang G; Li Y; Shi W; Zhong B; Yu H Mol Biol Rep; 2022 Sep; 49(9):8359-8368. PubMed ID: 35764749 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity. Liu Y; Piao H; Gao Y; Xu C; Tian Y; Wang L; Liu J; Tang B; Zou M; Cheng G Int J Nanomedicine; 2015; 10():2295-311. PubMed ID: 25848251 [TBL] [Abstract][Full Text] [Related]
6. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer. Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate. Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044 [TBL] [Abstract][Full Text] [Related]
8. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192 [TBL] [Abstract][Full Text] [Related]
9. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy. Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551 [TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies. Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262 [TBL] [Abstract][Full Text] [Related]
11. Repurposing of camptothecin: An esterase-activatable prodrug delivered by a self-emulsifying formulation that improves efficacy in colorectal cancer. Fang T; Ye Z; Chen X; Wang Y; Wan J; Wang H Int J Pharm; 2021 Apr; 599():120399. PubMed ID: 33647408 [TBL] [Abstract][Full Text] [Related]
12. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects. Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086 [TBL] [Abstract][Full Text] [Related]
13. Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation. He W; Du Y; Wang T; Wang J; Cheng L; Li X Int J Pharm; 2021 Sep; 606():120856. PubMed ID: 34229071 [TBL] [Abstract][Full Text] [Related]
14. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan. Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937 [TBL] [Abstract][Full Text] [Related]
15. Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin. Si J; Zhao X; Gao S; Huang D; Sui M Int J Pharm; 2019 Sep; 568():118499. PubMed ID: 31299338 [TBL] [Abstract][Full Text] [Related]
16. Relationship Between Increased Fucosylation and Metastatic Potential in Colorectal Cancer. Osuga T; Takimoto R; Ono M; Hirakawa M; Yoshida M; Okagawa Y; Uemura N; Arihara Y; Sato Y; Tamura F; Sato T; Iyama S; Miyanishi K; Takada K; Hayashi T; Kobune M; Kato J J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27628655 [TBL] [Abstract][Full Text] [Related]
17. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448 [TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations. Mosallaei N; Mahmoudi A; Ghandehari H; Yellepeddi VK; Jaafari MR; Malaekeh-Nikouei B Eur J Pharm Biopharm; 2016 Jul; 104():42-50. PubMed ID: 27108266 [TBL] [Abstract][Full Text] [Related]
19. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy. Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956 [No Abstract] [Full Text] [Related]